– 50-week global study to enroll ~350 patients across broad ALS population – Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS January 14, 2020 08:30 AM Eastern Standard Time BOSTON–(BUSINESS...
SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 /PRNewswire/ — Quantum Leap Healthcare Collaborative™ and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve...
Leading companies are using advanced study start-up application to speed clinical trials Accelerating study start-up is a top priority among leading life sciences companies. With this shift underway, an increasing number of organizations are selecting Vault Study...
PRINCETON, N.J., Jan. 14, 2020 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today...
FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato™ platform January 14, 2020 07:00 AM Eastern Standard Time...
Mechelen, Belgium; 13 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205. PINTA is a randomized, double-blind, placebo-controlled Phase 2 trial...
Email
Text